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Cystic Fibrosis (CF) is one of the most common single-gene defects in European descent populations with an incidence of about 1 in
every 2500 live births and carrier frequency of approximately 1 in 25. The most common mutation at the CF transmembrane conductance
regulator (CFTR) gene is a deletion (p.F508del) of the phenylalanine codon 508; its frequency, however, is not the same throughout the
world. The purpose of this paper is to document an application of a two-tier survey design in different states of Brazil, from which regional
differences of the incidence of CF and frequency of CF-causing mutation(s) carriers can be for the first time estimated. We present data on
genotype distributions in reference to p.F508del mutation in samples of newborns, adult controls and CF patients from five Brazilian states,
in which a total of 2683 newborns born to Brazilian white parents and 500 African-Brazilians adult controls were screened, as well as 300 CF
patients (262 European descents and 38 African descents) were genotyped. Our results suggest that the CF-incidence in different parts of
Brazil may differ by almost 20-fold. For the five different states as a whole, nearly 48% of the CF-alleles carry the p.F508del mutation, which
places the estimates of disease incidence and carrier frequencies for the Brazilian European descents as 1 in 7576 live births and 2.3%,
respectively. The implications for prevention of CF and other rare Mendelian diseases through such surveys of mutation screening are
discussed.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; p.F508del; Brazil; Incidence; Screening; Two-tier DNA1. Introduction
Cystic fibrosis (CF) is one of the most common single-
gene defect in European descent populations with an
incidence of about 1 in every 2500 live births and carrier
frequency of approximately 1 in 25 [1]. Over 1000 mutations
at the CF transmembrane conductance regulator (CFTR)
protein gene have been identified, several of which are⁎ Corresponding author.
E-mail address: genetika@genetika.com.br (S. Raskin).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.03.006known to have the same clinical symptoms of CF [2,3]. The
most common mutation causing CF is a deletion (p.F508del)
of the phenylalanine codon 508 located in the first
nucleotide-binding domain (NBF1) of the CFTR protein
gene. The frequency of the p.F508del mutation, however, is
not the same throughout the world, nor is it an exclusively
predictive indicator of the affection status for CF or carriers
of CF allele. In other words, affected individuals as well as
carriers of CF may not have the p.F508del mutation in their
genotypes. For example, among CF patients, the frequency
of p.F508del varies from 26% in Turkey and Algeria to 88%ed by Elsevier B.V. All rights reserved.
Table 1
Genotypes observed for p.F508del mutation screening in different states of
Brazil
State Among CF patients1 Among
controls
+/+ +/− −/− Total (m) +/− Total (n)
Rio Grande do Sul (RS)⁎ 15 22 16 53 13 528
Santa Catarina (SC)⁎ 15 23 10 48 5 500
São Paulo (SP)⁎ 14 29 11 54 3 511
Parana (PR)⁎ 9 21 20 50 5 528
Minas Gerais (MG)⁎ 16 22 19 57 4 616
Afro-Brazilians ⁎⁎ 2 5 31 38 1 500
Total 71 122 107 300 31 3183
Total ⁎ 69 117 76 262 30 2683
1,+ is the abbreviation for p.F508del mutation, so that +/+ denotes the
genotypes homozygous for this mutant allele, +/− among CF patients are
compound heterozygotes, whereas +/− are p.F508del carriers among
controls.
m=number of CF patients typed for p.F508del mutations, and n=number of
controls screened for ΔF508.
⁎European descents.
⁎⁎African descents (38 patients of African ancestry from the state of Minas
Gerais (MG) and 500 adult controls from state of Parana (PR).
Total with ⁎: Excluding the patients of African ancestry from the state of
Minas Gerais (MG).
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where the p.F508del mutation accounts for less than 50% of
the CF alleles, CF patients may often be compound hetero-
zygous of other mutations at the CFTR gene locus [6–9].
Thus, a single-tier screening for the p.F508del mutations
among newborns, without any adjustment for non-specificity
of the p.F508del mutation in CF-causing allele bearers,
as done in some surveys [e.g. [10]], may not provide an
accurate estimate of mutation frequencies or CF incidence in
populations. To make such adjustments, earlier we proposed
a two-tier mutation survey design (one in a random sample of
newborns and the other among CF patients) to estimate the
population incidence of a rare Mendelian genetic disease
and its mutant allele(s) carriers [11]. This type of survey,
as shown earlier [11], is capable of detecting regional (or
country-wide) differences of disease prevalence and carrier
frequencies, that are important in special reference to CF and
p.F508del mutation frequencies in carriers [8]. As there are
now several published studies showing that in different states
of Brazil, the frequency of the p.F508del and other CFTR
mutations and their haplotypes distribution in Brazilian CF
patients are not uniform [9,12–25], the purpose of this paper
is to document an application of the two-tier survey design in
different states of Brazil, from which regional differences of
the incidence of CF and CF-causing mutation(s) carriers can
be for the first time estimated.
We present data on genotype distributions in reference to
p.F508del mutation in samples of newborns, adults and CF
patients from the Brazilian states of Rio Grande do Sul (RS),
Santa Catarina (SC), Parana (PR), Sao Paulo (SP), and Minas
Gerais (MG), in which a total of 2683 newborns born to
Brazilian white parents and 500 African-Brazilians adults
were screened, as well as 300 CF patients (262 European
descents and 38 African descents) were genotyped. Our
results suggest that the CF-prevalence in different parts of
Brazil may differ by almost 20-fold (from 1 in 32,258 live
births in SP to 1 in 1587 in RS), while the differences of
prevalence of carriers of CF mutation(s) is more modest
(from approximately 1 in 90 in SP to 1 in 20 in RS), although
this difference is not statistically significant (at 5% level).
For the five different states as a whole, nearly 48% of the
CF-alleles carry the p.F508del mutation, which places the
estimates of disease and carrier prevalence for the Brazil-
ian European descents as 1 in 7576 live births and 2.3%,
respectively. The sampling errors of these estimates are also
provided, with reference to their implications for prevention
of CF and other rare Mendelian diseases through such
surveys of mutation screening.
2. Materials and methods
2.1. Subject population
The populations of Brazil, because of their unique
anthropological characteristics, provide some distinctive
features that must be taken into consideration for anymutation-screening program for genetic diseases. Brazil is
the largest country of the South American continent. Brazil
has a population of approximately 170 million [26], making
it the fifth most populous country in the world, and shows
regional variation of ethnic composition. Portugal conquered
Brazil in 1500, but various other European, Middle Eastern,
and Asian immigrant groups have settled in Brazil since the
middle-19th century. Africans were brought to Brazil as
slaves during the sixteenth to the nineteenth century and
indigenous people of Tupi and Guarani language stock were
natives. Although admixture was widespread, European
descendants relatively free from admixture are found pri-
marily in the South, like in the states of Parana (PR), Santa
Catarina (SC) and Rio Grande do Sul (RS) [27,28]. Inter-
marriage between the Portuguese and indigenous people or
African slaves was relatively common mainly in the early
times, and therefore the five large regions of Brazil (South,
Southeast, West-Central, Northeast and North) vary in ethnic
background. Today, Brazilian of European origin makes up
54% of the total population, mixed-race populations 39.9%,
African-Brazilian 5.4%, and Brazilian of Asian origin 0.5%.
In MG there is a high proportion of European/African
mixed-race descends (38%) as compared to PR and SC (17%
and 7% respectively); MG population is made up of 54%
Brazilians of European origin and 7.3% of African-Brazilian.
To account for the impact of these regional differences of
ethnic composition of the country, we sampled a total of 262
European-descent CF patients and 2683 white newborns.
The patient samples from each state varied from 48 in SC to
57 in MG (shown in Table 1) and the newborn sample from
500 in SC to 616 in MG. In addition to patients of European
17S. Raskin et al. / Journal of Cystic Fibrosis 7 (2008) 15–22origin, from MG an additional sample of 38 CF patients of
African descent was also sampled to detect the presence of
p.F508del mutation. We also tested for the p.F508del CFTR
mutation a sample from 500 non-CFAfrican-Brazilians adult
individuals living in PR, who have been previously ex-
tensively studied by our group [29–31]. We decided to
choose this sample as a African-descent control because as
the criteria to distinguish between the “white” and “non-
white” phenotype in this sample was as rigorous as possible
and done by only one of us (Culpi) who collected the sample
during a period of three years and divided it in four sub-
phenotypes depending on the criteria suggested by Krieger
et al. [32], Azevedo et al. [33] and Azevedo [34].
Each of these five states is served by well-established CF
regional centers. Fifty four percent of the CF patients were
male and the mean age was 6.7 years, ranging from 2 months
to 32 years. All patients and all their parents were born in
Brazil and belong to the first four generations of immigrants.
The geographic origin of the CF chromosomes was ascer-
tained by analyzing the birthplace of parents and the four
grandparents. From the geographic distribution of the
mutations, only unambiguous data was analyzed. From the
initial MG sample of 95 CF subjects, 38 exhibited signs of
African descend by the criteria suggested by Krieger et al.
[32], Azevedo et al. [33] and Azevedo [34], and they have at
least one African-Brazilian parent and therefore were
considered African-Brazilians; fifty seven CF patients born
in MG were of European descends.
2.2. Criteria for diagnosis of CF
Criteria for diagnosis included clinical findings of chronic
pulmonary disease and positive sweat test. The clinical
evaluation was carried out from 1990 to 2000.
General outcome variables included age at diagnosis;
sweat chloride concentration (in millimoles per liter) mea-
sured by quantitative pilocarpine iontophoresis; current
weight and height percentiles; the Shwachman–Kulczycki
clinical score, which is a subjective assessment of activity,
the physical examination, growth, and nutrition; and the
chest film. Respiratory status was assessed by tests of forced
vital capacity; forced expiratory volume in one second,
pseudomonas colonization; and chest-film score. Pseudo-
monas colonization was defined as the first positive cul-
ture after a series of negative cultures (or as the first positive
culture on record). Categorical data about pancreatic
status (i.e., whether function was sufficient or insufficient)
were requested. In addition, the patient's age at the onset
of pancreatic insufficiency was requested, if applicable.
The occurrence of several common complications of cystic
fibrosis was recorded: history of nasal polyps; meconium
ileus; distal intestinal obstruction syndrome, defined as
the need for enemas, intestinal lavage, or surgery after
the neonatal period; pancreatitis; diabetes mellitus, defined
as insulin dependence; biliary cirrhosis; and gallbladder
disease.2.3. Criteria for inclusion as European descend or African
descend
Patients were characterized as Brazilian of European
origin if they were phenotypically white and both parents
have European ancestry. Patients were characterized as
African-Brazilians if they were not phenotypically white and
at least one of the parents has African origin. The “white”
and “non-white” phenotype has been assigned based on
known criteria such as skin color, hair color and type, lips
and nose shape, as described by Krieger et al. [32], Azevedo
et al. [33] and Azevedo [34].
2.4. Blood samples and DNA analysis
Blood samples were collected by venopuncture or by
fingerstick on Guthrie cards, from which DNA was di-
rectly extracted by methods as described in Raskin et
al. [22,35,36]. Samples were tested for the p.F508del
CFTR mutation by protocols described in these earlier
reports. The genotype data, thus collected, give the
genotype frequencies in relation to the p.F508del mutation
in the CF patients (abbreviated as +/+, +/− and −/−, with
+ denoting the p.F508del mutation allele and −, all other
CF mutations) that are shown in Table 1. In addition,
Table 1 also shows the counts of +/− in the samples of
newborns.
2.5. Statistical analysis
The proportion of the p.F508del allele among all CF
patients (denoted by r) was estimated by gene count from
the genotype data [11] with its standard error (S.E.)
evaluated from the usual binomial distribution. From the
second tier of samples of newborns, the proportion of the p.
F508del allele (denoted by p), is also estimated similarly
with p=n1 /2n, where n1 is the counts of p.F508del
heterozygotes in a sample of n newborns. The estimated p
and r values are then subsequently inserted in Eqs. (8) and
(9) of Chakraborty et al. [11] to estimate the incidence of
CF and frequency of CF-mutation(s) carriers in the
different samples. The standard errors of these estimates
were evaluated by using the formulae (3) and (4) of
Chakraborty et al. [11]. For the five different states as a
whole, two alternative sets of estimators of the p.F508del
allele among CF patients, total frequency of all CF-causing
alleles, disease incidence and carrier frequencies were
employed; one that uses the theory as described above
[11] and the other by taking weighted average of the five
different sets of estimates (with weights proportional to the
inverse of their respective sampling variance [37]), the
latter directly leading to a heterogeneity chi-square statistic,
testing for the significance of regional differences of the
sample estimates [37]. Finally, the confidence limits of the
estimates were computed by the theory as described in
Chakraborty et al. [11].
Table 3
Parameter estimates from p.F508del mutation screenings in the total sample
from Brazil
Parameter
and
estimates
For the total sample of Euro-Brazilians Afro-
Brazilians
From total data a Combined estimate b
Proportion of from p.F508del mutation in CF alleles (r):
Estimate 0.487 0.486 0.118
S.E. 0.022 0.022 0.037
c.v. 0.045 0.045 0.313
CF allele frequency (d):
Estimate 0.0115 0.0086 0.0084
S.E. 0.0022 0.0019 0.0088
c.v. 0.188 0.216 1.047
CF-homozygote frequency (d 2):
Estimate 1.32×10−4 0.50×10−4 0.71×10−4
S.E. 0.49×10−4 0.26×10−4 1.49×10−4
c.v. 0.375 0.532 2.094
CF-carrier frequency [2d(1−d)]:
Estimate 0.0227 0.0173 0.0167
S.E. 0.0042 0.0037 0.0174
c.v. 0.185 0.213 1.038
a Estimated from pooled data from five states (i.e., summed genotype
frequencies).
b Computed fromweighted averages of parameter estimates from individual
state data (see Table 2).
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Table 1 shows the raw data of the two-tier screening surveys
conducted in the five states, as well as their total. The patient
sample of African-descent, collected from the state of Minas
Gerais (MG), and the Afro-Brazilian population sample
collected from PR are listed separately, and consequently, two
different totals are listed for this tier of the survey, one excluding
these Afro-Brazilian subjects and the other with all subjects
included. In all, 262 patients of European ancestry and 2683
newborns of the same ethnicity are included in these analyses.
As expected, among the newborns, no p.F508del homozygote
was observed, although nearly 48% of the CF alleles in the
pooled CF patients' sample carried the p.F508del mutation.
In Table 2 we present the estimates, standard errors (S.E.),
coefficient of variation (c.v.=estimate /S.E.) of the propor-
tion (r) of the CF alleles carrying the p.F508del mutation, CF
allele frequency (d), incidence of CF (d2), and CF-carrier
frequency [2d(1−d)] in the five states, along with the
heterogeneity chi-square (χ2) for each of the estimates.
Several observations can be made from these estimates.
State-to-state variation in the proportion of the p.F508del
allele among the CF patients (r) is seen in the data (from 39%
in PR to 55% in SC). However, this variation does not appear
to the statistically significant (χ2 =6.40 with 4 df, P≈0.2),
probably due to somewhat large standard errors of the state-
specific estimates (between 4.7% to 5.1%). Likewise,
variations of the state-specific estimates of the CF-causing
alleles (d) frequency (between 0.56% in SP to 2.51% in RS),
the incidence of CF (d2, from 0.31 in SP to 6.3 in RS per
10,000 live births) and frequency of CF-carriers (2d(1−d),
from 1.11% in SP to 4.89% in RS) are also noticeable, but not
statistically significant (at 5% level).Table 2
Parameter estimates from p.F508del mutation screening in different states of Braz
Parameters
and
estimates
States
RS SC PR
Proportion of p.F508del mutation in CF alleles (r):
Estimate 0.491 0.552 0.390
S.E. 0.049 0.051 0.049
c.v. 0.099 0.092 0.125
CF allele frequency (d):
Estimate 0.0251 0.0091 0.0121
S.E. 0.0073 0.0041 0.0056
c.v. 0.293 0.455 0.463
CF-homozygote frequency (d 2) :
Estimate 6.30×10−4 0.82×10−4 1.47×
S.E. 3.69×10−4 0.75×10−4 1.37×
c.v. 0.586 0.911 0.927
CF-carrier frequency [2d(1−d)]:
Estimate 0.0489 0.0179 0.0240
S.E. 0.0140 0.0081 0.0110
c.v. 0.285 0.451 0.458
1The estimates for Minas Gerais (MG) are based on European descent patients on
S.E.= its standard error evaluated from the usual biomial distribution.
c.v.=coefficient of variation (c.v.=estimate /S.E.) of the proportion (r) of the CFThe consequences of state-to-state variation of these esti-
mates are also evident when the data from these five states
are pooled for analysis. The results are shown in Table 3,
where two different approaches are taken for estimation. In
the first, the total sample (of 2683 newborns and 262 CF
patients of European descent) is used to estimate each of the
parameters (shown under the column of total data), and in the
second, the weighted average of the state-specific estimates
were computed (with weights proportional to the inverse ofil
χ2
(4 df)
SP MG1
0.528 0.474 6.40
0.048 0.047
0.091 0.099
0.0056 0.0069 6.57
0.0032 0.0035
0.584 0.509
10−4 0.31×10−4 0.47×10−4 3.44
10−4 0.36×10−4 0.48×10−4
1.167 1.018
0.0111 0.0136 6.74
0.0064 0.0069
0.580 0.505
ly.
alleles carrying the Δ508 mutation.
Table 4
Points estimates and 95% confidence limits of CF-homozygote and carrier
frequencies in Brazil, expressed as 1 in n individuals
State Incidence of
CF-homozygotes
Incidence of
CF-carriers
Euro-Brazilians: RS 1 in 1587 ( 504–5005) 1 in 20 (12–36)
SC 1 in 12,195 (2044–72,690) 1 in 56 (23–135)
PR 1 in 6803 (1103–41,720) 1 in 42 (17–102)
SP 1 in 32,258 (3281–318,549) 1 in 90 (29–282)
MG 1 in 21,277 (2895–156,449) 1 in 73 (27–198)
Total a 1 in 7576 (3633–15,802) 1 in 44 (31–63)
Combined b 1 in 20,202 (8651–47,179) 1 in 58 (38–88)
Afro-Brazilians 1 in 14,085 (231–850,965) 1 in 60 (8–458)
a Estimated from pooled data from five states (i.e., summed genotype
frequencies).
b Computed from weighted averages of parameter estimates from
individual state data (see Table 2).
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column of combined estimate. While the estimate of the
proportion (r) of the p.F508del mutation among the CF
patients is nearly identical (49%) by both methods, those for
the frequency (d) of all CF-causing alleles, disease incidence
(d2) and carrier frequencies [2d(1−d)] are higher for the total
data in comparison to the weighted average of state-specific
estimates. In particular, the disease incidence in the total data
is almost 2.64-fold higher (1.32 per 10,000 live births as
opposed to the combined estimate of 0.5 per 10,000 live
births). Of course, of all the parameter estimates, the disease
incidence is most poorly estimated (with a coefficient of
variation of over 37% for the total data and over 53% for the
combined estimate).
In Table 4 we present the state-specific as well as
combined point estimates of the incidence of CF and carrier
frequency and their 95% confidence intervals. The wide
confidence intervals reflect the inherent errors of estimation
of frequencies of rare events (distributed as a Poisson
variant). Nevertheless, in the Southern states (e.g., in RS)
cystic fibrosis can be as common as in Scotland and Northern
Europe, with an apparent decreasing trend in the Southeast-
ern states. Table 4 also lists the point estimates and 95%
confidence interval estimates of the CF-carrier frequencies in
the individual states and for the pooled sample as a whole.
As expected, the rank correlation of the disease incidence
(d2) and carrier frequencies [2d(1−d)] is 100%, generally
decreasing from South to Southeastern states. Also worth
noting is that the carrier frequency estimates are in general
more precise than the estimates of disease incidences.
4. Discussion
Data presented here show that a two-tier screening for the p.
F508del mutation of the CFTR gene in CF patients and
newborns can be used to estimate the disease incidence and
carrier frequencies in five different states of Brazil. In general,
our data indicate a South to Southeastern decreasing trend of
disease incidence and carrier frequencies in Brazil, consistentwith the ethnic composition of the populations (more people of
European descent in South). The pooled data shows that in
these five states, the overall frequency of CF is probably more
comparable with that of Southern Europe (Italy, Spain and
Portugal, and considerably less than that in Denmark, Scotland
and other northern European countries [2,5].
The estimates of the prevalence of p.F508del allele among
the CF chromosomes ranging between 39% in Parana to 55%
in Santa Catarina (Table 2) also suggest that the predictive
power of this mutation alone for detecting CF in Brazil is
comparable with that of Italy and South Europe and
considerably lower than that of Denmark, Scotland and
Northern Germany [4].
Although we had p.F508del mutation data in 38 CF
patients of African-descent from the state of Minas Gerais
(shown in Table 1), we have not included that series in any
subsequent analysis. However, this series shows that in
individuals of African descent in MG, the prevalence of the
p.F508del mutation in CF patients is considerably lower
(11.8±3.7%) than that of the CF patients of European
decent. Further, the genotype distribution in this sample is
significantly different from that of the Hardy–Weinberg
expectations ((χ2 =5.20 with 1 df, and −2lnL=3.68;
Pb0.02, by a permutation test). We ascribe this to the
admixed nature of African-Brazilians. Further, the finding of
only one p.F508del mutation in 1000 CF chromosomes from
Afro-Brazilians adults living in PR, suggests that this
mutation is 6 times less frequent in Afro-Brazilians than in
the general population of Euro-Brazilians. Since CF is rare in
African populations and most of the CF-alleles in Africa,
Afro-Americans, Afro-Latin Americans and in African-
Brazilians patients are not due to the p.F508del mutation
[9,38,45,46], and the only one p.F508del mutation in 1000
CF chromosomes from Afro-Brazilians adults living in PR
was found in an adult classified as “light mulato”, that is, the
phenotype closest to “white”, we conclude that the Afro-
Brazilian patients probably received their p.F508del muta-
tions during the admixture events in their families.
In this context it may be worth mentioning that our data
is also consistent with the recent report of such a two-tier
survey conducted in the Rio de Janeiro population of Brazil
[18]. These authors estimated that the frequency of the p.
F508del allele among the CF patients is 30.7% (a figure
somewhat lower than our state-specific estimates, which may
be due to the fact that Cabello et al. did not try to differentiate
between CF patients of European descends and African
descends) and the disease incidence is 1 in 3542 live births
(95% CI from 1 in 340 to 1 in 36,895, applying the method
of the present paper). Applying the method of the present
paper, we additionally estimate that the carrier frequency as 1
in 30 individuals (95% CI as 1 in 10 to 1 in 96) in the Rio de
Janeiro population. These are within the range of our state-
specific estimates, supporting the consistent nature of such
two-tier mutation-screening data.
We are cognizant that our results should be taken with
caution, as there may be some ascertainment bias; 1) due to
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difficulties to determine the criteria to differentiate indivi-
duals of unmixed European descent from those who are
admixed in Brazil. Even Brazilians initially considered of
“European origin” are not completely free of admixture. The
high admixture rates in the Brazilian population not only
carries CF alleles from Brazilian descends of Europeans to
African-Brazilians (such as ΔFF508) but also carries alleles
from African-Brazilians to Brazilian descends of Europeans
[9]. Although these difficulties to divide Brazilians based on
their phenotype and ancestry obviously may have compro-
mised the accuracy of our estimates, data arising from
statewide CF newborn mandatory screening programs,
recently established in SC, PR and MG states, show that
our estimates fit very close to the incidence that is now being
reported in these newborn screening programs [39]; 2) Some
authors have questioned the validity of genotyping the CF
patients by the p.F508del mutation alone (as done in the
data of the present paper). For example, Feingold et al. [40]
found significant departures of such genotype data from
the Hardy–Weinberg expectation, suggesting the presence
of ascertainment bias in relation to the severity of diseases
in patient registry data. To entertain such a possibility in
the present data, we performed a test of Hardy–Weinberg
proportions in our samples. Either by the chi-square or
likelihood ratio test [41], none of the five samples show any
significant (at 5% level) departure from Hardy–Weinberg
expectations of genotype frequencies in the patient series
data. Thus, we conclude that ascertainment bias or misdiag-
nosis of our detection method for the p.F508del mutation is
not an issue in the present survey. The patient series data of
the Rio de Janeiro survey [18] also shows consistency with
the Hardy–Weinberg expectation (χ2 =1.73 with 1 df, and
−2lnL=1.68; PN0.25); 3) Another ascertainment bias could
be introduced by the fact that the “true” p.F508del CFTR
mutation frequency in patients could only be determined very
early in life, such as in the neonate period after newborn
screening of CF, because the p.F508del CFTRmutation could
be underrepresented in a cohort of “older” patients, as CF
patients homozygous for the p.F508del CFTR mutation may
have a severe phenotype and could die before they are
diagnosed and/or referred to regional CF centers, “lowering”
the p.F508del CFTR mutation frequency in a cohort of
patients. This should be at least in part true in a country such
as Brazil, where CF is still largely underdiagnosed. 4) This
bias may be counterbalanced by the fact that many CF
patients that have mild disease are also not diagnosed in
countries such as Brazil, and therefore, the p.F508del CFTR
mutation frequency in a cohort of “severe”CF patients would
be higher. Future data coming from the CF newborn
screening programs now starting in Brazil will help to
determine the strength of each of this two last ascertainment
bias; 4) The fact that parameter estimates for African-descent
were done by comparing patients and controls of African-
descent samples coming from two different states of Brazil.
As we concluded that the Afro-Brazilian patients from MGprobably received their p.F508del mutations during the
admixture events in their families, we believe that the p.
F508del mutation frequency in Afro-Brazilian patients will
vary from state to state, according to their state-specific
admixture rates with Euro-Brazilians. For the same reason,
we believe that the number of p.F508del mutations that will
be found in future studies of African-descent controls living
in other states in Brazil than PR, will be directly related to the
admixture with European descent in the sample. As far as we
know, no p.F508del mutation was ever reported in non-
admixture Afro-Brazilians from Africa [38].
In general, the fact that less than one-half of the CF alleles
are ascribed to the p.F508del mutation in South and
Southeastern parts of Brazil raises some concerns about the
efficiency of mutation-screening programs for CF in Brazil.
As pointed out by Ten Kate [42], with 50% of the CF alleles
detected as p.F508del, only one-quarter of couples at risk in
Brazil can be found. Therefore, if a p.F508del-based carrier-
screening program is set up in Brazil, manymore couples will
be detected where one member will carry the p.F508del
mutation, whereas the possibility of carrying an undetected
CF-causing allele in the other member cannot be ruled out.
Since these couples are at significantly increased risk of
having a CF child, the efficiency of a screening program with
ability to detect only the p.F508del mutation will be greatly
reduced. Also, if the Brazilian government decides to
establish a two-tier CF newborn screening program based
on testing for p.F508del all positive newborn samples
measured for immunoreactive trypsin (IRT), many IRT-
positive newborns will be detected carrying one copy of the p.
F508del mutation, whereas the possibility of carrying an
undetected CF-causing allele in the other allele cannot be
ruled out, neither the possibility that they will be only
asymptotic carriers, bringing up serious ethical implications
in CF newborn screening [43]. Thus, the data presented in this
paper, as well as previous works showing heterogeneity in the
CFTR gene pool in Brazil [9,12–25], indicates that other
mutations detected at the CFTR locus that are prevalent in
Brazil need to be included in mutation-screening programs
for prevention of CF in Brazil. In a comprehensive recent
worldwide survey, this has been shown to be valid for other
populations [44].
In summary, the application of the two-tier screening
survey for the p.F508del mutations shows, for the first time,
that in individuals of European ancestry in Brazil, the
incidence of CF and carrier frequencies are comparable to
those in Southern Europe. Statistical homogeneity of the
estimates and the consistency with Hardy–Weinberg expec-
tations of genotypes in the patient series suggest that the
genetic structure of the populations of European descent in
Brazil is by and large unaffected by population substructure.
However, the individuals of African descent (in MG)
probably received their CF alleles during admixture with
individuals of European descent. This study also indicates
that the overall ΔFF508 frequency in Brazil may be lower
than the previously reported 47% in Brazilians of European
21S. Raskin et al. / Journal of Cystic Fibrosis 7 (2008) 15–22decent. Although this frequency is still valid for Brazilian CF
patients of European origin (as showed by the average
frequency of the five states in this study), the overall
prevalence of the ΔFF508 mutation should be lower when
data from other Brazilian states arise, as the contributions of
the African gene pool in populations of other states of Brazil
are considerable (e.g., in 18 of the 27 states of Brazil Afro-
Brazilians are in majority; [26]). Considering this heteroge-
neity of the Brazilian population, the inter-regional migra-
tion, and the different ethnic composition of each region, one
might expect that the frequency of CF mutations, as well as
the incidence of CF, will vary between different regions and
populations of Brazil, as well as in Latin America. Because
regional differences in ethnic composition will influence
both cost-benefit analyses and risk assessments, uniform
policies regarding population screening of CF patients and
carriers may not be appropriate in a country such as Brazil,
characterized by striking ethnic diversity and regional
differences in prevalent European and African ancestries.
Based on the fact that the disease is clearly underdiag-
nosed in Brazil and Latin America, the data presented in this
work show that it is now possible to estimate the incidence of
CF in different states. Further, since the majority of CFTR
mutations are known in some Southern states of Brazil, we
suggest that a CF neonatal screening program in the Southern
states of Brazil using a two-tier approach (biochemical plus
DNA test) should be immediately established, although a
general newborn screening program for the entire country
should be plannedmore carefully. But since less than one-half
of the CF alleles in Brazil can be ascribed to the p.F508del
mutation, it is important that other prevalent CF mutations in
Brazil be included in the molecular step of the two-tier
screening program that we propose.
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